<DOC>
	<DOCNO>NCT01392989</DOCNO>
	<brief_summary>Allogeneic stem cell transplantation ( transplant blood cell another individual ) treatment option patient Myelodysplasia Myeloproliferative Disorders . During course study , attempt learn whether particular type blood cell , call Cytokine Induced Killer ( CIK ) cell may add benefit allogeneic stem cell transplantation . CIK cell present small quantity bloodstream number expand brief period nurture laboratory .</brief_summary>
	<brief_title>Post T-plant Infusion Allogeneic Cytokine Induced Killer Cells Consolidative Therapy Myelodysplastic Syndromes/Myeloproliferative Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Neural Tube Defects</mesh_term>
	<mesh_term>Spinal Dysraphism</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>4.1.1 Recipient Inclusion Criteria start ATG/TLI : Diagnosis Myelodysplastic Syndrome Criteria ( A ) Diagnosis MDS classifiable WHO system Refractory Anemia Refractory Cytopenia Multilineage Dysplasia MDSunclassified Refractory Cytopenias Multilineage Dysplasia Ringed Sideroblasts , Refractory Anemia Excess Blasts1 Refractory Anemia Excess Blasts2 Chronic myelomonocytic leukemia ( CMML ) MDS transform acute leukemia . Patients advanced MDS must &lt; 10 % marrow blast prior receive condition TLI/ATG . Less 10 % marrow blast must document marrow examination within 1 month start conditioning . If necessary , cytoreductive regimen determine refer center . Patients evolution AML require morphologic leukemia freestate blast &lt; 5 % ( 50 ) . Myeloproliferative Disorders B ) Myeloproliferative disorder include : Idiopathic Myelofibrosis Polycythemia vera Essential Thrombocythemia Chronic Myelomonocytic Leukemia Chronic Neutrophilic Leukemia Chronic Eosinophilic Leukemia Philadelphia chromosomenegative CML . Hypereosinophilic Syndrome Systemic Mastocytosis Patients MPD must &lt; 10 % marrow blast prior receive condition TLI/ATG . Less 10 % marrow blast must document marrow examination within 1 month start conditioning . If necessary , cytoreductive regimen determine refer center . Patients evolution AML require morphologic leukemiafree state le 5 % marrow aspirate . Presence residual dysplastic feature follow cytoreductive therapy acceptable . Therapyrelated myeloid neoplasms Patients tMDS must &lt; 10 % marrow blast prior receive condition TLI/ATG . Less 10 % marrow blast must document marrow examination within 1 month start conditioning . If necessary , cytoreductive regimen determine refer center . Patients tAML require morphologic leukemia freestate blast &lt; 5 % . 2 . Patient age &gt; 50 year , patient &lt; 50 year age preexist medical condition prior therapy consider high risk regimenrelated toxicity associate conventional myeloablative transplant . 3 . A fully HLA match single antigen/allele mismatch sibling unrelated donor available . 4.2 Donor Eligibility 4.2.1 Inclusion Criteria Related Donors 1 . Donors must HLAmatched one allele mismatch . 2 . Donor age &lt; 75 unless clear Principal Investigator 3 . Donor must consent peripheral blood stem cell ( PBSC ) mobilization GCSF apheresis 4 . Donor must consent placement central venous catheter event peripheral venous access limit . 4.1.2 Recipient Exclusion Criteria 1 . Uncontrolled CNS involvement disease 2 . Females pregnant 3 . Organ dysfunction define follow : Cardiac function : ejection fraction ( EF ) &lt; 35 % uncontrolled cardiac failure Pulmonary : DLCO &lt; 40 % predict Liver function abnormality : elevation bilirubin &gt; 3 mg/dl and/or AST ALT &gt; 3x upper limit normal Estimated creatinine clearance &lt; 50 ml/min 4 . Karnofsky performance score ( KPS ) &lt; 70 % ( Appendix F ) 5 . Documented fungal disease progressive despite treatment 6 . Viral infection : HIV positive patient eligible protocol . Hepatitis B C positive patient evaluate casebycase basis 7 . Patients prior malignancy diagnose &gt; 5 year ago without evidence disease eligible . Patients prior malignancy treat &lt; 5 year ago life expectancy &gt; 5 year malignancy eligible . 4.1.3 Recipient Exclusion Criteria proceed CIK infusion 1 . Uncontrolled infection 2 . Evidence disease relapse 3 . Grade 2 GVHD ( Grade 1 GVHD evaluate Principal Investigator ) 4 . Does meet release criterion CIK cell .2.2 Exclusion Criteria Related Donor 1 . Identical twin 2 . Pregnant lactating female 3 . Prior malignancy within precede five year , exception nonmelanoma skin cancer . 4 . HIV seropositivity 4.2.3 Unrelated Donor Inclusion Criteria 1 . Donors must HLAmatched one allele antigen mismatch . 2 . Donor must consent PBSC mobilization GCSF apheresis well collection donation plasma . Bone marrow unrelated donor eligible protocol .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>